Compare Aurora Cannabis Inc (ACB) vs iShares MSCI India ETF (INDA) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

INDA, the iShares MSCI India ETF, trades at $49.88 with a 0.65% daily gain, showing bullish technical momentum with strong moving average signals. The ETF provides exposure to Indian equities, which face mixed sentiment due to AI transition challenges and geopolitical risks, though India's economy grew 7.8% in Q1 2026. Technical indicators show neutral oscillators but overall bullish bias with key support at $49.

The outlook remains cautiously optimistic with India's strong GDP growth offset by sector-specific headwinds. Investment opportunity lies in India's economic expansion and discounted valuation versus S&P 500, while risks include monsoon uncertainties, Middle East tensions affecting inflation, and foreign investor outflows of $26.4 billion in 2026.